比色法测定胃乐益冲剂中薯蓣皂苷元的含量

目的建立胃乐益冲剂中薯蓣皂苷元的含量测定方法。方法采用紫外分光光度法，最大吸收波长406 nm。结果薯蓣皂苷元在0.002 4～0.012 0 mg·mL^-1浓度范围内与吸光度呈良好的线性关系，r＝0.999 7(n＝5)，平均回收率为98.37%，RSD＝2.25%(n＝5)。结论该方法简便快速，灵敏度高，重现性好，适用于该制剂的质量控制。     

益肾养元颗粒中大黄素的含量测定

目的:建立益肾养元颗粒中大黄素的含量测定方法.方法:采用 C18柱,以甲醇- 0.2%磷酸( 75 : 25)为流动相,检测波长为 291 nm.结果:大黄素与其他组分峰的分离度 > 1.5,理论塔板数以大黄素峰计算为 4 100;大黄素线性范围是 0.053～ 0.840 μ g, r=0.999 6;平均回收率为 100.17%, RSD为 2.12%.结论:反相高效液相色谱法简便、快速、重现性好,适用于益肾养元颗粒的质量控制.     

咳特灵颗粒提取工艺研究

目的优选咳特灵颗粒的提取工艺.方法以干膏得率和芦丁的含量作为指标,考虑不同的煎煮时间、加水量、含醇量,采用正交实验法,确定最佳提取工艺.结果最佳的提取工艺为煎煮时间第1次1.5 h,第2次1.0 h、加溶媒体积14(8 6)倍、含醇量80%.结论该提取工艺为制备咳特灵颗粒的最佳提取工艺.     

Pharmacological and structural characterization of a novel phospholipase A2 from Micrurus dumerilii carinicauda venom.

We have isolated a new phospholipase A2 (MiDCA1) from the venom of the coral snake Micrurus dumerilii carinicauda. This toxin, which had a molecular mass of 15,552Da, shared high sequence homology with the PLA2 toxins MICNI A and B from Micrurus nigrocinctus venom (77.7% and 73.1%, respectively). In chick biventer cervicis preparations, MiDCA1 produced concentration- and time-dependent neuromuscular blockade that reached 100% after 120 min (2.4 microM, n = 6); contractures to exogenously applied carbachol (8 microM) and KCl (13 mM) were still seen after complete blockade. In mouse phrenic-nerve diaphragm preparations, MiDCA1 (2.4 microM; n = 6) caused triphasic changes followed by partial neuromuscular blockade. Intracellular recordings of end-plate potentials (EPPs) and miniature end-plate potentials (MEPPs) from mouse diaphragm preparations showed that MiDCA1 increased the quantal content by 386+/-12% after 10 min (n = 14; p<0.05) and caused a triphasic change in the frequency of MEPPs. MiDCA1 also decreased the resting membrane potential, an effect that was prevented by tetrodotoxin and/or low extracellular calcium, but not by d-tubocurarine. The toxin increased the amplitude of mouse sciatic-nerve compound action potentials by 30+/-9% (0.6 microM; p<0.05). Potassium currents elicited in freshly dissociated dorsal root ganglia neurones were blocked by 31+/-1% (n = 4; p<0.05) in the presence of 2.4 microM MiDCA1. These results show that MiDCA1 is a new presynaptic phospholipase A2 that produces neuromuscular blockade in vertebrate nerve-muscle preparations. The triphasic effects seen in mammalian preparations and the facilitatory response were probably caused mainly by the activation of sodium channels, complemented by the blockade of nerve terminal potassium channels. The inability of d-turocurarine to prevent the depolarization by MiDCA1 indicated that cholinergic nicotinic receptors were not involved in this phenomenon.     

SPE—HPLC法测定菊延保康颗粒中蒙花苷的含量

目的:建立测定菊延保康颗粒中蒙花苷含量的方法。方法:选用Oasis HLB固相萃取小柱对样品进行纯化。采用C_(18)色谱柱(4.6mm×250 mm,5μm),以甲醇-0.8%磷酸(1:1)为流动相,流速为1 mL·min~(-1),检测波长为326 nm。结果:蒙花苷进样量在0.0432—2.16μg的范围内与峰面积呈良好的线性关系,r为0.9999,平均回收率为100.4%。结论:本方法操作简便快速,结果准确可靠。     

HPLC法测定舒心颗粒中丹参素钠的含量

目的:建立舒心颗粒中有效成分丹参素钠的含量测定方法.方法:用HPLC法测定.以十八烷基硅烷键合硅胶为填充剂,色谱柱Dirmonsil C18(4.6mm×250mm,5μm),流动相甲醇-1%磷酸(15:85),流速0.8mL·min-1;检测波长280nm.柱温30℃.结果:丹参素钠在0.374～3.366μg与其峰面积值呈良好的线性关系(r=0.9999),精密度RSD为0.43%,平均回收率为97.77%,RSD为1.22%.结论:该方法简便易行,结果准确可靠,可用于舒心颗粒产品质量控制.     

复方甘草酸苷联合人工肝治疗重型肝炎疗效观察

目的:观察复方甘草酸苷联合人工肝治疗重型肝炎的疗效。方法:将58例重型肝炎患者随机分为治疗组和对照组,对照组除给予基础治疗外,根据患者情况每隔3d～5d行血浆置换或血液灌流,每位患者一般做5次～10次;治疗组在对照组治疗的基础上给予复方甘草酸苷治疗。结果:治疗组与对照组总有效率分别为64.52%、40.74%,二者间有显著性差异(P<0.05);治疗8wk时治疗组肝功能改善情况优于对照组(P<0.05)。结论:复方甘草酸苷联合人工肝治疗重型肝炎有效、安全。     

复方甘草酸苷联合氧化苦参碱治疗慢性乙型肝炎疗效观察

目的:观察复方甘草酸苷联合氧化苦参碱治疗慢性乙型肝炎的临床疗效。方法:将66例慢性乙型肝炎患者随机分为2组。治疗组36例,给予复方甘草酸苷联合氧化苦参碱治疗;对照组30例,给予甘草酸二铵治疗。用药8wk后观察2组临床症状、体征、肝功能及肝纤维化指标变化。结果:治疗组在临床症状、体征、肝功能及肝纤维化指标的改善方面较对照组有显著性差异(P<0.05)。结论:复方甘草酸苷联合氧化苦参碱治疗慢性乙型肝炎临床疗效明显优于甘草酸二铵。     

复方甘草酸苷联合化疗治疗消化道恶性肿瘤的疗效观察

目的:观察复方甘草酸苷注射液联合化疗治疗中、晚期消化道恶性肿瘤的疗效和毒副反应。方法:将100例患者随机均分为复方甘草酸苷联合化疗组(治疗组)和单纯化疗组(对照组),比较2组疗效和毒副反应。结果:治疗组和对照组近期有效率分别为58%、36%(P<0·05)。治疗组无肝功能损害,消化道反应占10%,程度轻;对照组肝功能损害占38%,消化道反应占44%,程度重(P<0·05)。结论:复方甘草酸苷注射液联合化疗治疗中、晚期消化道恶性肿瘤可提高疗效,预防药物性肝损害的发生,减轻消化道反应程度。     

复方甘草酸苷治疗活动性肝炎肝硬化的疗效观察

目的:观察复方甘草酸苷长程治疗活动性肝炎肝硬化的疗效。方法:58例活动性肝炎肝硬化患者静脉注射复方甘草酸苷60ml,1次/d,连用18mo。观察治疗前、后的临床症状、体征、生化指标、病毒学指标的变化。结果:治疗后有35例患者活动性肝硬化得到控制,5例患者腹水消失,17例患者恢复工作;HBV-DNA定量下降>103拷贝/ml,HBeAg转阴率达33.3%。结论:复方甘草酸苷长程治疗活动性肝炎肝硬化,可改善患者肝功能,阻止病情进展,提高其生活质量。